Last week, our Senior Project Lead, Kelsi Smith, was invited to speak at the Singapore Clinical Research Institute (SCRI) Clinical Trials Symposium 2026.
Kelsi joined the session on Pragmatic Clinical Trials and Real-World Evidence, alongside an expert panel of researchers and industry specialists.
Her presentation explored register-based randomized trials and how they may support evidence generation across both clinical practice and Phase III development.
Drawing on Nordic experience, Kelsi discussed established registers such as SWEDEHEART and presented a potential framework for EBV vaccine trials.
The panel discussion also highlighted several important questions:
🔹 How can healthcare systems establish a culture that supports high-quality, longitudinal data collection?
🔹 What infrastructure is needed to develop and maintain research-ready registers?
🔹 Where can pragmatic approaches offer efficiencies in cost and time compared with traditional randomized controlled trials?
These questions are increasingly relevant as regulators explore how real-world data and clinical trials can complement one another.
Both the EMA and FDA have established frameworks and initiatives supporting the use of real-world evidence in regulatory decision-making.
For us, the discussion reinforced an important point: strong RWE depends not only on access to data, but on thoughtful study design, appropriate infrastructure, and methodological rigour.
Interested in how register-based studies or RWE could support your evidence-generation strategy? Get in touch with our team.
